Viyash Scientific Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Viyash Scientific Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 75% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 98% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹424 of operating cash. Higher than 98% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹424Over the last 3 years, every ₹100 of reported profit came with ₹424 of operating cash.
Higher than 98% of Healthcare companies in India.
Self-Funding Ratio
2.6×Over the last 3 years its own operating cash covered its investment spending (capex) 2.6 times.
Higher than 75% of Healthcare companies in India.
Cash Locked Ratio
₹34For every ₹100 of sales, ₹34 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹30 tied up three years earlier.
More money tied up than 69% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹15Sales grew 137% in 3 years; of every extra ₹100 of sales, ₹15 became extra profit.
Lower than 52% of Healthcare companies in India.
Asset Productivity Ratio
+137% / +203%In 3 years sales changed by +137% while total assets changed by +203%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.4×Debt due within a year is covered 2.4 times by its yearly operating cash.
Higher than 61% of Healthcare companies in India.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 54% of Healthcare companies in India.
Tangible Assets Ratio
79%Of every ₹100 the company owns, ₹79 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 83% of Healthcare companies in India.
Tangible Net Worth Ratio
67%Of every ₹100 of net worth, ₹67 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 83% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Viyash Scientific Limited owes ₹0.33 for every ₹1 it owns. Net profit rose 664% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
50.9Investors pay ₹50.9 for every ₹1 of Viyash Scientific Limited's yearly profit, higher than 70% of Healthcare companies in India.
P/B ratio
3.15The share price is 3.15 times Viyash Scientific Limited's book value per share, lower than 69% of Healthcare companies in India.
Market cap
₹9,180 CrThe total market value of all of Viyash Scientific Limited's shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹2,911 CrWhat Viyash Scientific Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹65.96Net worth divided by the number of shares. The share price of ₹207.99 is 3.2 times this, which is the P/B above.
Return on equity (ROE)
6.1%Viyash Scientific Limited earned 6.1% on its shareholders' money over the last year, lower than 81% of Healthcare companies in India.
Owes vs Owns
0.33×Viyash Scientific Limited owes ₹0.33 for every ₹1 it owns (low), lower than 61% of Healthcare companies in India.
Dividend yield
NoneViyash Scientific Limited does not currently pay a dividend.
Revenue growth
+13%Revenue rose 13% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Profit growth
+664%Net profit rose 664% in the year to Mar 2026.
Profit margin
5.3%Viyash Scientific Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
1.8×Cash from Viyash Scientific Limited's business was 1.8× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
7.1×Viyash Scientific Limited's operating profit covered its interest costs 7.1 times in the year to Mar 2026.
Cash vs debt
Net debtViyash Scientific Limited had ₹220 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Viyash Scientific Limited's P/E ratio?
Investors pay ₹50.9 for every ₹1 of Viyash Scientific Limited's yearly profit, higher than 70% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Viyash Scientific Limited: ₹9,180 Cr ÷ ₹2,911 Cr (31 Mar 2026) = 3.2.
What is Viyash Scientific Limited's return on equity?
Viyash Scientific Limited earned 6.1% on its shareholders' money over the last year, lower than 81% of Healthcare companies in India.
How much does Viyash Scientific Limited owe compared with what it owns?
Viyash Scientific Limited owes ₹0.33 for every ₹1 it owns (low), lower than 61% of Healthcare companies in India.
Does Viyash Scientific Limited pay a dividend?
No. Viyash Scientific Limited does not currently pay a dividend.
Is Viyash Scientific Limited's revenue growing?
Revenue rose 13% in the year to Mar 2026, and grew 33% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.